US2003130193A1PendingUtilityA1

GCSF conjugates

51
Priority: Jan 29, 1999Filed: Dec 30, 2002Published: Jul 10, 2003
Est. expiryJan 29, 2019(expired)· nominal 20-yr term from priority
Inventors:Pascal Bailon
A61P 43/00A61K 47/60C07K 14/535
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Physiologically active PEG-GCSF conjugates having a formula as follows: are described, as well as compositions containing a mixture of each conjugates in which m and n can be different integers for the conjugates in the composition.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A physiologically active conjugate having the formula  
       
         
           
           
               
               
           
         
         wherein G is a granulocyte colony stimulating factor less the amino group or groups thereof which form an amide linkage with a polyethylene glycol moiety in the conjugate; R is lower alkyl; n is an integer from 420 to 550; and m is an integer from 1 to 5.  
       
     
     
         2 . The conjugate of  claim 1  wherein R is methyl.  
     
     
         3 . The conjugate of  claim 2  wherein n is from 450 to 490.  
     
     
         4 . The conjugate of  claim 2  wherein m is an integer from 1 to 4.  
     
     
         5 . The conjugate of  claim 4  wherein m is 2.  
     
     
         6 . The conjugate of  claim 1  wherein the granulocyte colony stimulating factor is GCSF Mutein having the sequence shown in FIG. 1.  
     
     
         7 . The conjugate of  claim 1  wherein n is from 450 to 490.  
     
     
         8 . The conjugate of  claim 1  wherein m is an integer from 1 to 4.  
     
     
         9 . The conjugate of  claim 8  wherein m is 2.  
     
     
         10 . The conjugate of  claim 1  wherein the granulocyte colony stimulating factor is GCSF Mutein having the sequence shown in FIG. 1.  
     
     
         11 . The conjugate of  claim 1 , which has a longer circulating half-life and greater in vivo granulopoietic activity than the corresponding unconjugated granulocyte colony stimulating factor.  
     
     
         12 . The conjugate of  claim 11 , wherein the granulocyte colony stimulating factor is GCSF Mutein having the sequence shown in FIG. 1.  
     
     
         13 . A physiologically active conjugate having the formula  
       
         
           
           
               
               
           
         
         wherein R is methyl; n is an integer from 450 to 490; m is 2; and G is GCSF Mutein having the sequence shown in FIG. 1 less the amino groups thereof which form an amide linkage with a polyethylene glycol moiety in the conjugate.  
       
     
     
         14 . A composition comprising physiologically active conjugates having the formula  
       
         
           
           
               
               
           
         
         wherein G in each of the conjugates is a granulocyte colony stimulating factor less the amino group or groups thereof which form an amide linkage with a polyethylene glycol moiety in the conjugates; R in each of the conjugates is independently lower alkyl; n in each of the conjugates is independently an integer from 420 to 550; in each of the conjugates m is independently an integer from 1 to 4; the percentage of conjugates where m is 1 is from eighteen to twenty-five percent; the percentage of conjugates where m is 2 is from fifty to sixty-six percent; the percentage of conjugates where m is 3 is from twelve to sixteen percent; and the percentage of conjugates where m is 4 is up to five percent.  
       
     
     
         15 . The composition of  claim 14 , wherein R is methyl in each of the conjugates.  
     
     
         16 . The composition of  claim 14 , wherein n and R are the same in each of the conjugates.  
     
     
         17 . The composition of  claim 14  wherein n is from 450 to 490.  
     
     
         18 . The composition of  claim 14  where in each of the conjugates the granulocyte colony stimulating factor is GCSF Mutein having the sequence shown in FIG. 1.  
     
     
         19 . A composition comprising physiologically active conjugates having the formula  
       
         
           
           
               
               
           
         
         wherein R is methyl; n in each of the conjugates is the same and is an integer from 450 to 490; G is GCSF Mutein having the sequence shown in FIG. 1 less the amino groups thereof which form an amide linkage with a polyethylene glycol moiety in the conjugate; in each of the conjugates m is independently an integer from 1 to 4; the percentage of conjugates where m is 1 is from eighteen to twenty-five percent; the percentage of conjugates where m is 2 is from fifty to sixty-six percent; the percentage of conjugates where m is 3 is from twelve to sixteen percent; and the percentage of conjugates where m is 4 is up to five percent.  
       
     
     
         20 . A method for producing a PEG-GCSF conjugate having a longer circulating half-life and greater in vivo granulopoietic activity than the corresponding unconjugated GCSF, which method consists of covalently linking a reagent of the formula  
       
         
           
           
               
               
           
         
         to the GCSF to produce said conjugate.  
       
     
     
         21 . The method of  claim 21 , wherein the GCSF is GCSF Mutein having the sequence shown in FIG. 1.

Join the waitlist — get patent alerts

Track US2003130193A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.